Darolutamide Interactions
Levetiracetam
No clinically significant drug interactions identified.
Levodopa/carbidopa
No clinically significant drug interactions identified.
Levofloxacin
No clinically significant drug interactions identified.
Levothyroxine
No clinically significant drug interactions identified.
Linagliptin
No clinically significant drug interactions identified.
Liraglutide
No clinically significant drug interactions identified.
Lisdexamphetamine
No clinically significant drug interactions identified.
Lisinopril
No clinically significant drug interactions identified.
Loperamide
No clinically significant drug interactions identified.
Lorazepam
No clinically significant drug interactions identified.
Losartan
No clinically significant drug interactions identified.
Memantine
No clinically significant drug interactions identified.
Metformin
No clinically significant drug interactions identified.
Methadone
No clinically significant drug interactions identified.
Methylphenidate
No clinically significant drug interactions identified.
Metoclopramide
No clinically significant drug interactions identified.
Metoprolol
No clinically significant drug interactions identified.
Metrondiazole
No clinically significant drug interactions identified.
Mirabegron
No clinically significant drug interactions identified.
Mirtazapine
No clinically significant drug interactions identified.
Misoprostol
No clinically significant drug interactions identified.
Montelukast
No clinically significant drug interactions identified.
Moxifloxacin
No clinically significant drug interactions identified.
Naltrexone
No clinically significant drug interactions identified.
Naproxen
No clinically significant drug interactions identified.
Nifedipine XL
No clinically significant drug interactions identified.
Nirapirib
Caution - increased level of niraparib due to BCRP inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Nitrofurantoin
No clinically significant drug interactions identified.
Nortriptyline
No clinically significant drug interactions identified.
Olanzapine
No clinically significant drug interactions identified.
Olaparib
No clinically significant drug interactions identified.
Omeprazole
No clinically significant drug interactions identified.
Ondansetron
No clinically significant drug interactions identified.
Orlistat
No clinically significant drug interactions identified.
Oxazepam
No clinically significant drug interactions identified.
Oxybutynin
No clinically significant drug interactions identified.
Oxycodone
No clinically significant drug interactions identified.
Pantoprazole
No clinically significant drug interactions identified.
Paroxetine
No clinically significant drug interactions identified.
Penicillin
No clinically significant drug interactions identified.
Perindopril
No clinically significant drug interactions identified.
Perinodopril
No clinically significant drug interactions identified.
Phenobarbital
Caution - potential decreased level of darolutamide due to 3A4 induction. Avoid use with additional concurrent inducers. Consider choosing an alternative agent.
Phenytoin
Avoid combination - decreased level of darolutamide due to 3A4/Pgp induction. Choose an alternative agent.
Pioglitazone
No clinically significant drug interactions identified.
Pravastatin
Caution - increased level of pravastatin due to OATP1B1 inhibition. Monitor for signs of toxicity (ie. CK). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Prazosin
No clinically significant drug interactions identified.
Prednisone
No clinically significant drug interactions identified.
Pregabalin
No clinically significant drug interactions identified.
Prochlorperazine
No clinically significant drug interactions identified.
Propranolol
No clinically significant drug interactions identified.
Quetiapine
No clinically significant drug interactions identified.
Rabeprazole
No clinically significant drug interactions identified.
Ramipril
No clinically significant drug interactions identified.
Ranitidine
No clinically significant drug interactions identified.
Relugolix
No clinically significant drug interactions identified.
Repaglinide
Caution - increased level of repaglinide due to OATP1B1 inhibition. Monitor for signs of toxicity (ie. hypoglycemia). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Risedronate
No clinically significant drug interactions identified.
Risperidone
No clinically significant drug interactions identified.
Rivaroxaban
Caution - increased level of rivaroxaban due to BCRP inhibition. Consider choosing an alternative agent.
Rivastigmine
No clinically significant drug interactions identified.
Rizatriptan
No clinically significant drug interactions identified.
Ropinirole
No clinically significant drug interactions identified.
Rosuvastatin
Avoid combination - increased level of rosuvastatin due to BCRP and OAT1B1/1B3 inhibition. Choose an alternative agent.
Saxagliptin
No clinically significant drug interactions identified.
Semaglutide
No clinically significant drug interactions identified.
Senna
No clinically significant drug interactions identified.
Sertraline
No clinically significant drug interactions identified.
Sildenafil
No clinically significant drug interactions identified.
Silodosin
No clinically significant drug interactions identified.
Simvastatin
Caution - increased level of simvastatin due to OAT inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Sitagliptin
No clinically significant drug interactions identified.
Solifenacin
No clinically significant drug interactions identified.
Spironolactone
No clinically significant drug interactions identified.
Sulfamethoxazole-trimethoprim
No clinically significant drug interactions identified.
Sumatriptan
No clinically significant drug interactions identified.
Tadalafil
No clinically significant drug interactions identified.
Talazoparib
Caution - increased level of talazoparib due to BCRP inhibiton. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Tamsulosin
No clinically significant drug interactions identified.
Telmisartan
No clinically significant drug interactions identified.
Temazepam
No clinically significant drug interactions identified.
Terazocin
No clinically significant drug interactions identified.
Terazosin
No clinically significant drug interactions identified.
Terbinafine
No clinically significant drug interactions identified.
Ticagrelor
No clinically significant drug interactions identified.
Tolterodine
No clinically significant drug interactions identified.
Topiramate
No clinically significant drug interactions identified.
Tramadol
No clinically significant drug interactions identified.
Tramadol-acetaminophen
No clinically significant drug interactions identified.
Trazodone
No clinically significant drug interactions identified.
Valacyclovir
No clinically significant drug interactions identified.
Valsartan
Caution - increased level of valsartan due to OAT inhibtion. Monitor for signs of toxicity (ie. SCr, K+). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Vardenafil
No clinically significant drug interactions identified.
Varenicline
No clinically significant drug interactions identified.
Venlafaxine
No clinically significant drug interactions identified.
Verapamil
No clinically significant drug interactions identified.
Vortioxetine
No clinically significant drug interactions identified.
Warfarin
Caution - monitor INR more closely after initiation of darolutamide therapy or dose changes. Potential increased toxicity of warfarin (bleeding) due to enzyme inhibition. Titrate warfarin dose to target INR.
Zolmitriptan
No clinically significant drug interactions identified.
Zolpidem
No clinically significant drug interactions identified.
